in a prospective multicenter study the efficacy and toxicity of an induction therapy with daunorubicin , cytosine-arabinoside and vp 16-213 , followed by an intensified consolidation with high-dose cytosine-arabinoside and daunorubicin , is evaluated in adult patients with acute myelogenous leukemia .
C0011015
daunorubicin
C0023467
acute myelogenous leukemia